EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single‐Center Study of 30 Patients

Vili Viljaharju, Tuomas Mertsalmi, K Amande M Pauls, Maija Koivu iD, Johanna Eerola-Rautio, Marianne Udd, Eero Pekkonen

Movement Disorders Clinical Practice · 2024-02 · 11 (2) · 159-165

DOI: 10.1002/mdc3.13926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 10.12.2023. Verfasst von Vili Viljaharju und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Catechols, Nitriles. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsingin Yliopisto, The Finnish Parkinson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levodopa‐entacapone‐carbidopa intestinal gel (LECIG) is a novel device assisted treatment option for advanced Parkinson's disease (PD). It has been available in Finland since 2020. There is paucity of scientific studies considering LECIG treatment in clinical practice.

Objectives

Objectives of this study were to evaluate the changes in medication, adverse events and early discontinuations of LECIG treatment in real life clinical practice.

Methods

The records of 30 consecutive patients, who received LECIG between years 2020 and 2022 in Helsinki University Hospital, were retrospectively analyzed. Data considering changes in medication, discontinuations, and adverse events during the first six months of LECIG treatment was collected.

Results

Mean levodopa equivalent daily dose (LEDD) rose significantly between baseline before LECIG and six months with treatment (1230 mg vs. 1570 mg, P = 0.001). Three patients were discarded during nasojejunal tube test phase and seven discontinued the treatment during six‐month follow‐up. Most common reasons for discontinuation were difficulty in finding suitable infusion rate and neuropsychiatric problems. Safety issues encountered were similar to those reported with levodopa‐carbidopa intestinal gel (LCIG) treatment. One case of rhabdomyolysis due to severe dyskinesia during LECIG treatment was observed. Patients were satisfied with the small size of the pump system.

Conclusions

LEDD seems to increase during the first months of LECIG treatment. When compared to studies on LCIG, safety profile of LECIG appears similar, but early discontinuation rate is higher than expected. However, long‐term studies are lacking. Only clear advantage to LCIG appears to be the smaller LECIG pump size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseCatecholsNitrilesHumansCarbidopaAntiparkinson AgentsRetrospective Studies

Stichwörter der Autor:innen

LECIGadvanced Parkinson's diseaselevodopa-entacapone-carbidopa intestinal gel

Substanzen

LevodopaCarbidopaentacaponeAntiparkinson AgentsCatecholsNitriles

Autor:innen und Institutionen

  • Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
  • Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland.
  • Department of Gastroenterological Surgery, Helsinki University Hospital, Helsinki, Finland.

ORCID-Profile: Maija Koivu

Förderung

  • Helsingin Yliopisto
  • The Finnish Parkinson Foundation

Zitieren

APA

Viljaharju, V., Mertsalmi, T., Pauls, K. A. M., Koivu, M., Eerola-Rautio, J., Udd, M., & Pekkonen, E. (2024). Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single‐Center Study of 30 Patients. Movement Disorders Clinical Practice, 11(2), 159-165. https://doi.org/10.1002/mdc3.13926

Vancouver

Viljaharju V, Mertsalmi T, Pauls KAM, Koivu M, Eerola-Rautio J, Udd M, et al. Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single‐Center Study of 30 Patients. Movement Disorders Clinical Practice. 2024;11(2):159-165. doi:10.1002/mdc3.13926

BibTeX
@article{Viljaharju2024,
  author = {Viljaharju, Vili and Mertsalmi, Tuomas and Pauls, K Amande M and Koivu, Maija and Eerola-Rautio, Johanna and Udd, Marianne and Pekkonen, Eero},
  title = {Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single‐Center Study of 30 Patients},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  volume = {11},
  number = {2},
  pages = {159--165},
  doi = {10.1002/mdc3.13926}
}
Kostenlos starten →